Citius Pharmaceuticals' LYMPHIR Resubmission Accepted by FDA
Monday, 18 March 2024, 13:26
Citius Pharmaceuticals Receives FDA Acceptance for LYMPHIR Resubmission
Citius Pharmaceuticals has announced that the FDA has accepted the resubmission of LYMPHIR, an innovative immunotherapy designed to address cutaneous T-cell lymphoma.
Promising Immunotherapy
The acceptance of the resubmission highlights the potential efficacy of LYMPHIR in treating this form of lymphoma.
Advancing Treatment Options
- LYMPHIR: A novel immunotherapy
- Focus: Cutaneous T-cell lymphoma treatment
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.